A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab.
Optimal treatment for HER2/neu-positive, node-positive early breast cancer should include the monoclonal antibody trastuzumab. This relatively new agent has shown very limited pulmonary toxicity. Our report describes a case of life-threatening interstitial pneumonitis associated with Guillain-Barré syndrome that occurred during the administration of adjuvant trastuzumab. The severity of the clinical presentation and the limited number of reports in the literature of acute trastuzumab-related lung injury make the description of this case of crucial interest.
Bettini
Anna Cecilia
AC
Division of Oncology, Ospedali Riuniti, Bergamo, Italy. acbettini@yahoo.com
Tondini
Carlo
C
Poletti
Paola
P
Caremoli
Elena Rota
ER
Guerra
Ugo
U
Labianca
Roberto
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D020275:Guillain-Barre Syndrome / Q000150:complications*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000209:etiology*; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab